On April 17, 2026, UCB, a global biopharmaceutical company, announced that it has entered into a definitive agreement under which UCB would acquire Neurona Therapeutics, including lead asset NRTX-1001, adding to UCB’s epilepsy portfolio. Neurona Therapeutics is a clinical-stage biotherapeutics company focused on advancing regenerative cell therapies for epilepsies and other disorders of the nervous system. Under the terms of the agreement, UCB will pay $650 million upfront and up to $500 million in potential future milestone payments, subject to certain closing conditions. Wilson Sonsini Goodrich & Rosati advised Neurona on the transaction.
The Wilson Sonsini team that advised Neurona on the transaction includes:
Mergers & Acquisitions
Robert T. Ishii
Brendan Mahan
Elia Perez Villamarin
Blake Kaufmann
Corporate
Lance Brady
Jacob Morales
Technology Transactions
Kenneth Clark
Lowell Segal
Vincent Bai
James Dunlop
Natalie Juo
Isaiah Loya
Corporate Finance
Dana Hall
Roshanne Arathoon
FDA Regulatory
Eva Yin
Data, Privacy, and Cybersecurity
Daniel Chen
Dan Shin
Tax
Myra Sutanto Shen
Ryan Wong
Anjali Krishnan
Employee Benefits and Compensation
Michelle Wallin
Gregory Hughes
Employment Litigation
Susannah Howard
Aren Balabanian
Matthew Chang
Antitrust and Competition
Jamillia Ferris
Kimberley Biagioli
National Security and Trade
Joshua Gruenspecht
Anne Seymour
Seth Cowell
Grace Beck
Real Estate
Susan Reinstra
Martin Sul
Alex Corluyan
For more information, please see UCB’s news release.
